Search Results

HOME > SEARCH > SEARCH RESULTS

Refine by Audience:

Your search for pilot research returned 182 results.

Selected filters: Patients

Displaying 31 to 40 of 182 records
Sort by: Page: << Prev 1… 2… 3… 4… 5… 6… 7… Next >>

Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients – Sep 27, 2023
A new imaging agent, Ga-68-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in JNM.
First Three Facilities Accredited in SNMMI/IAC Radiopharmaceutical Therapy Accreditation Program – Sep 25, 2023
SNMMI and the Intersocietal Accreditation Commission are pleased to announce the first three facilities to be awarded the new Radiopharmaceutical Therapy Accreditation.
Nuclear Medicine Treatment Cures Lethal Form of Ovarian Cancer in Preclinical Setting – Sep 18, 2023
A new 225Ac-DOTA-based pre-targeted radioimmunotherapy system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects, according to research published in JNM.
JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy – Sep 1, 2023
SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with Lu-177 PSMA radionuclide therapy.
PSMA PET/CT Waives the Need for Pre-Imaging Biopsy in Elderly Patients – Aug 14, 2023
In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy, according to new research published in JNM.
Clinical Trials Network – Aug 3, 2023
The SNMMI Clinical Trials Network provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Increased standardization in trials leads to better data that then results in expanded utilization of radiopharmaceuticals.
FDA Fully Approves Leqembi for Alzheimers; CMS Unclear on PET Reimbursement – Jul 10, 2023
The FDA has granted full approval to Leqembi (lecanemab); however, CMS has not committed to reimbursement of the needed PET scans.
SNMMI Keeps Eye on the Patient at 2023 Annual Meeting – Jun 28, 2023
SNMMI hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed Eye on the Patient, held in Chicago, Illinois.
Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease – Jun 27, 2023
A novel PET perfusion radiotracer, F-18 flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to Tc-99m SPECT myocardial perfusion imaging, according to research presented at the 2023 SNMMI Annual Meeting.
Personalized Dosing in Prostate Cancer Treatment Improves Patient Outcomes – Jun 27, 2023
By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.

Displaying 31 to 40 of 182 records
Page: << Prev 1… 2… 3… 4… 5… 6… 7… Next >>